PMID: 9174193Jun 1, 1997Paper

In vitro activity of HSR-903, a new quinolone

Antimicrobial Agents and Chemotherapy
Y TakahashiT Nishino

Abstract

The in vitro activity of the new fluoroquinolone HSR-903 was compared with those of ciprofloxacin, lomefloxacin, sparfloxacin, and levofloxacin. HSR-903 inhibited 90% of methicillin-susceptible and -resistant Staphylococcus aureus (MRSA) clinical isolates at 0.78 and 1.56 microg/ml, respectively, and its activity against MRSA was 16-fold higher than those of sparfloxacin and levofloxacin and 64-fold higher than that of ciprofloxacin. The MICs at which 90% of the isolates are inhibited (MIC90s) of HSR-903 for Streptococcus pyogenes and penicillin G-susceptible and -resistant Streptococcus pneumoniae (PRSP) were 0.10, 0.05, and 0.05 microg/ml, respectively. Against PRSP, the activity of HSR-903 was 4-fold higher than that of sparfloxacin and 32- to 256-fold higher than those of the other quinolones. The MIC90 of HSR-903 for Enterococcus faecalis was 0.20 microg/ml, and HSR-903 was more active than the other quinolones against enterococci. The activity of HSR-903 against members of the family Enterobacteriaceae and Pseudomonas aeruginosa was roughly similar to that of ciprofloxacin and greater than those of the other quinolones. Against Haemophilus influenzae, Moraxella catarrhalis, and Helicobacter pylori, HSR-903 was the most po...Continue Reading

References

May 1, 1991·The Journal of Infectious Diseases·G W KaatzC A Ruble
Jun 1, 1991·The Journal of Infectious Diseases·H M BlumbergI K Wachsmuth
Nov 1, 1990·The Journal of Antimicrobial Chemotherapy·M TanakaT Nishino
Nov 1, 1989·Antimicrobial Agents and Chemotherapy·T KojimaS Mitsuhashi
Jun 1, 1988·Antimicrobial Agents and Chemotherapy·K FujimakiS Mitsuhashi
Aug 1, 1988·Antimicrobial Agents and Chemotherapy·S R Norrby, M Jonsson
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·T UneY Osada
Jun 1, 1987·Antimicrobial Agents and Chemotherapy·T HiroseS Mitsuhashi
Jan 1, 1983·Methods in Enzymology·R Otter, N R Cozzarelli
Oct 1, 1982·Antimicrobial Agents and Chemotherapy·K SatoS Mitsuhashi
Apr 1, 1994·The Journal of Antimicrobial Chemotherapy·J M Domagala

❮ Previous
Next ❯

Citations

Jul 30, 2005·Journal of Veterinary Pharmacology and Therapeutics·G A AlbarellosM F Landoni
Oct 12, 2018·Journal of Veterinary Pharmacology and Therapeutics·Maria Fabiana Landoni, Gabriela Alejandra Albarellos
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Shuichi MiyazakiKeizo Yamaguchi
Jul 2, 1999·Antimicrobial Agents and Chemotherapy·A WatanabeT Nukiwa
Apr 29, 1998·Antimicrobial Agents and Chemotherapy·S YoshizumiK Yamaguchi
May 29, 1999·Antimicrobial Agents and Chemotherapy·Y NikiO Matsuoka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.